Aviragen Therapeutics Inc  

(Public, NASDAQ:AVIR)   Watch this stock  
Find more results for NASDAQ:BOTA
-0.02 (-1.46%)
Real-time:   2:53PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.34 - 1.36
52 week 1.23 - 2.66
Open 1.34
Vol / Avg. 15,727.00/51,919.00
Mkt cap 52.16M
P/E     -
Div/yield     -
EPS -1.02
Shares 38.64M
Beta 0.82
Inst. own 36%
Sep 9, 2016
Q4 2016 Aviragen Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 5, 2016
Q3 2016 Aviragen Therapeutics Inc Earnings Release
May 5, 2016
Q3 2016 Aviragen Therapeutics Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -98.11% -77.64%
Operating margin -98.11% -79.27%
EBITD margin - -88.62%
Return on average assets -33.08% -19.75%
Return on average equity -37.85% -24.42%
Employees 19 -
CDP Score - -


2500 Northwinds Pkwy Ste 100
ALPHARETTA, GA 30009-2248
United States - Map
+1-301-7703099 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Aviragen Therapeutics, Inc., formerly Biota Pharmaceuticals Inc., is a biopharmaceutical company. The Company is focused on the discovery and development of direct-acting antivirals to treat infections. It has approximately four product candidates in clinical development that address viral infections that have limited therapeutic options. Its product candidates include vapendavir, which is an oral treatment for human rhinovirus (HRV) infections in moderate-to-severe asthmatics that is being evaluated in its Phase IIb SPIRITUS trial; BTA074, a Phase II topical antiviral treatment for genital warts caused by human papillomavirus (HPV) types 6 and 11; BTA585, an oral fusion (F) protein inhibitor in Phase IIa development for the treatment and prevention of respiratory syncytial virus (RSV)-A and RSV-B infections, and laninamivir octanoate in Phase II development for the treatment of influenza A and B infections. It also has preclinical RSV non-fusion inhibitor program.

Officers and directors

Mark P. Colonnese Chief Financial Officer, Executive Vice President
Age: 60
Bio & Compensation  - Reuters
Russell H. Plumb Executive Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Joseph M. Patti Ph.D. President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Armando Anido Independent Director
Age: 57
Bio & Compensation  - Reuters
Geoffrey F. Cox Ph.D. Independent Director
Age: 71
Bio & Compensation  - Reuters
Michael R. Dougherty Independent Director
Age: 57
Bio & Compensation  - Reuters
Michael W. Dunne M.D. Independent Director
Age: 55
Bio & Compensation  - Reuters
John P. Richard Independent Director
Age: 58
Bio & Compensation  - Reuters